Claudia Capparelli, Ph.D.

Kimmel Cancer Center at Jefferson University

Education:

University of Calabria, Italy, Ph.D., Cell Biochemistry and Drug Activity in Oncology

University of Calabria, Italy, B.S. and M.S., Pharmaceutical Chemistry and Technology

Research Focus:

Dr. Capparelli studies are focused on the role of neuregulin1/ErbB3 pathway in melanoma. Specifically, she is studying neuregulin1 as cancer promoter in wild-type BRAF/NRAS (WT/WT). This WT/WT group represents approximately 30% of melanomas. Whereas the FDA has approved three different targeted therapeutic agents for BRAFV600E melanoma, there are no targeted inhibitors approved for the WT/WT group. Secondly, she is analyzing the role of neuregulin 1 as a tumor microenvironmental factor that promotes drug resistance in vemurafenib treated BRAFV600E melanoma. The RAF inhibitors are first-line treatment for the 50% of melanomas that harbor BRAFV600E mutations; however, the response is variable and progression is almost inevitable. Her studies are addressing unmet needs in the melanoma field: to develop new treatment strategies for wild-type BRAF/NRAS patients and to improve RAF inhibitor-based treatments for mutant BRAF patients.

« Back to Scholar Overview

Copyright 2017 Outrun the Sun, Inc.
Name and Logo are registered trademarks.
Site Design by Mitre Agency